

**ISOVUE-M- iopamidol injection, solution**  
**Bracco Diagnostics Inc**

-----  
**ISOVUE-M® 200**  
**Iopamidol Injection 41%**  
**ISOVUE-M® 300**  
**Iopamidol Injection 61%**

DIAGNOSTIC  
NONIONIC RADIOPAQUE CONTRAST MEDIA  
For Intrathecal Administration in Neuroradiology  
Including Myelography (Lumbar, Thoracic, Cervical,  
Total Columnar) Pediatric Myelography (Lumbar, Thoracic),  
and for Contrast Enhancement of Computed Tomographic (CECT)  
Cisternography and Ventriculography

**DESCRIPTION**

ISOVUE-M (Iopamidol Injection) formulations are stable, aqueous, sterile, and nonpyrogenic solutions for intrathecal administration.


Each mL of ISOVUE-M 200 (Iopamidol Injection 41%) provides 408 mg Iopamidol with 1 mg tromethamine and 0.26 mg edetate calcium disodium. The solution contains approximately 0.029 mg (0.001 mEq) sodium and 200 mg organically bound iodine per mL.

Each mL of ISOVUE-M 300 (Iopamidol Injection 61%) provides 612 mg Iopamidol with 1 mg tromethamine and 0.39 mg edetate calcium disodium. The solution contains approximately 0.043 mg (0.002 mEq) sodium and 300 mg organically bound iodine per mL.

The pH of ISOVUE-M contrast media has been adjusted to 6.5-7.5 with hydrochloric acid and/or sodium hydroxide. Pertinent physicochemical data are noted below. ISOVUE-M (Iopamidol Injection) is hypertonic as compared to plasma and cerebrospinal fluid (approximately 285 and 301 mOsm/kg water, respectively).

Parameter	Iopamidol	
	41%	61%
Concentration (mg/mL)	200	300
Osmolality @ 37° C (mOsm/kg water)	413	616
Viscosity (cP) @ 37° C	2.0	4.7
@ 20° C	3.3	8.8
Specific Gravity @ 37° C	1.216	1.328

Iopamidol is designated chemically as (S)-N,N'-bis[2-hydroxy-1-(hydroxymethyl)-ethyl]- 2,4,6-triiodo-5-lactamidoisophthalamide. Structural formula:



MW 777.09

C<sub>17</sub>H<sub>22</sub>I<sub>3</sub>N<sub>3</sub>O<sub>8</sub>

CAS-60166-93-0

Organically Bound Iodine: 49%

## CLINICAL PHARMACOLOGY

The pharmacokinetics of intravenously administered iopamidol in normal subjects conform to an open two-compartment model with first order elimination (a rapid alpha phase for drug distribution and a slow beta phase for drug elimination). The elimination serum or plasma half-life is approximately two hours; the half-life is not dose dependent. No significant metabolism, deiodination, or biotransformation occurs.

Iopamidol is rapidly absorbed into the bloodstream from cerebrospinal fluid (CSF); following intrathecal administration, iopamidol appears in plasma within one hour and virtually all of the drug reaches the systemic circulation within 24 hours. Iopamidol is excreted mainly through the kidneys following intrathecal administration, and the drug is essentially undetectable in the plasma 48 hours later. In patients with impaired renal function, the elimination half-life is prolonged dependent upon the degree of impairment. In the absence of renal dysfunction, the cumulative urinary excretion for iopamidol, expressed as a percentage of administered intravenous dose is approximately 35 to 40 percent at 60 minutes, 80 to 90 percent at 8 hours, and 90 percent or more in the 72- to 96-hour period after administration. In normal subjects, approximately 1 percent or less of the administered dose appears in cumulative 72- to 96-hour fecal specimens.

Iopamidol displays little tendency to bind to serum or plasma proteins.

No evidence of *in vivo* complement activation has been found in normal subjects.

Animal studies indicate that iopamidol does not cross the blood-brain barrier to any significant extent following intravascular administration.

## INDICATIONS AND USAGE

ISOVUE-M (Iopamidol Injection) is indicated for intrathecal administration in adult neuroradiology including myelography (lumbar, thoracic, cervical, total columnar), and for contrast enhancement of computed tomographic (CECT) cisternography and ventriculography. ISOVUE-M 200 (Iopamidol Injection) is indicated for thoraco-lumbar myelography in children over the age of two years.

## CONTRAINDICATIONS

Intrathecal administration of corticosteroids with iopamidol is contraindicated. Because of overdose considerations, immediate repeat myelography in the event of technical failure is contraindicated (see interval recommendation under **DOSAGE AND ADMINISTRATION**). Myelography should not be performed in the presence of significant local or systemic infection where bacteremia is likely.

## WARNINGS

The need for myelographic examination should be carefully evaluated. Iopamidol should be administered with caution in patients with increased intracranial pressure or suspicion of intracranial

tumor, abscess or hematoma, those with a history of convulsive disorder, severe cardiovascular disease, chronic alcoholism, or multiple sclerosis, and elderly patients.

Particular attention must be given to state of hydration, concentration of medium, dose, and technique used in these patients.

Contrast media may promote sickling in individuals who are homozygous for sickle cell disease when injected intravenously or intra-arterially. Although ISOVUE-M is not injected intravascularly, measurable plasma levels are attained after intrathecal administration of iopamidol.

If frankly bloody cerebrospinal fluid is observed, the possible benefits of a myelographic examination should be considered in terms of risk to the patient.

Patients on anticonvulsant medication should be maintained on this therapy.

Direct intracisternal or ventricular administration for standard radiography (without computerized tomographic enhancement) is not recommended. Inadvertent intracranial entry of a large or concentrated bolus of the contrast medium, which increases the risk of neurotoxicity, can be prevented by careful patient management. Also, effort should be directed to avoid rapid dispersion of the medium causing inadvertent rise to intracranial levels (e.g., by active patient movement). If such intracranial entry of the medium occurs, prophylactic anticonvulsant treatment with diazepam or barbiturates orally for 24 to 48 hours should be considered.

Use of medications that may lower the seizure threshold (phenothiazine derivatives, including those used for their antihistaminic properties; tricyclic antidepressants; MAO inhibitors; CNS stimulants; analeptics; antipsychotic agents) should be carefully evaluated. While the contributory role of such medications has not been established, some physicians have discontinued these agents at least 48 hours before and for at least 24 hours following intrathecal use.

Focal and generalized motor seizures have been reported after intrathecal use of water-soluble contrast agents including iopamidol. In several of those cases reported with iopamidol, higher than recommended doses were employed. Therefore *avoid*:

- Deviations from recommended neuroradiologic procedure or patient management.
- Use in patients with a history of epilepsy unless medically justified.
- Overdosage.
- Intracranial entry of a bolus or premature diffusion of a high concentration of the medium.
- Failure to maintain elevation of the head during the procedure, on the stretcher, and in bed.
- Excessive and particularly active patient movement or straining.

**Severe Cutaneous Adverse Reactions** Severe cutaneous adverse reactions (SCAR) may develop from 1 hour to several weeks after intravascular contrast agent administration. These reactions include Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN), acute generalized exanthematous pustulosis (AGEP) and drug reaction with eosinophilia and systemic symptoms (DRESS). Reaction severity may increase and time to onset may decrease with repeat administration of contrast agent; prophylactic medications may not prevent or mitigate severe cutaneous adverse reactions. Avoid administering Isovue-M to patients with a history of a severe cutaneous adverse reaction to Isovue-M.

## PRECAUTIONS

### General

Diagnostic procedures which involve the use of any radiopaque agent should be carried out under the direction of personnel with the prerequisite training and with a thorough knowledge of the particular procedure to be performed. Appropriate facilities should be available for coping with any complication of the procedure, as well as for emergency treatment of severe reaction to the contrast agent itself. After parenteral administration of a radiopaque agent, competent personnel and emergency facilities should be available for at least 30 to 60 minutes since severe delayed reactions may occur.

Preparatory dehydration is dangerous and may contribute to acute renal failure in patients with advanced vascular disease, diabetic patients, and in susceptible nondiabetic patients (often elderly with preexisting renal disease). *Patients should be well hydrated prior to and following iopamidol administration.*

The possibility of a reaction, including serious, life-threatening, fatal, anaphylactoid or cardiovascular reactions, should always be considered (see **ADVERSE REACTIONS**). Patients at increased risk include those with a history of a previous reaction to a contrast medium, patients with a known sensitivity to iodine per se, and patients with a known clinical hypersensitivity (bronchial asthma, hay fever, and food allergies). The occurrence of severe idiosyncratic reactions has prompted the use of several pretesting methods. However, pretesting cannot be relied upon to predict severe reactions and may itself be hazardous for the patient. It is suggested that a thorough medical history with emphasis on allergy and hypersensitivity, prior to the injection of any contrast medium, may be more accurate than pretesting in predicting potential adverse reactions. A positive history of allergies or hypersensitivity does not arbitrarily contraindicate the use of a contrast agent where a diagnostic procedure is thought essential, but caution should be exercised. Premedication with antihistamines or corticosteroids to avoid or minimize possible allergic reactions in such patients should be considered (see **CONTRAINDICATIONS**).

Reports indicate that such pretreatment does not prevent serious life-threatening reactions, but may reduce both their incidence and severity.

The possibility of inducing bacterial meningitis in patients during intrathecal procedures should always be considered. To avoid bacterial contamination during spinal puncture, a sterile field should be maintained at all times.

If nondisposable equipment is used, scrupulous care should be taken to prevent residual contamination with traces of cleansing agents.

### **Information for Patients**

Patients receiving injectable radiopaque diagnostic agents should be instructed to:

1. Inform your physician if you are pregnant.
2. Inform your physician if you are diabetic or if you have multiple myeloma, pheochromocytoma, homozygous sickle cell disease, or known thyroid disorder.
3. Inform your physician if you are allergic to any drugs, food, or if you had any reactions to previous injections of substances used for x-ray procedures (see **PRECAUTIONS-General**).
4. Inform your physician about any other medications you are currently taking, including nonprescription drugs, before you have this procedure.
5. Advise patients to inform their physician if they develop a rash after receiving Isovue-M.

### **Drug Interactions**

Other drugs should not be admixed with iopamidol (see **CONTRAINDICATIONS, and DOSAGE AND ADMINISTRATION, Drug Incompatibilities**).

### **Drug/Laboratory Test Interactions**

The results of PBI and radioactive iodine uptake studies, which depend on iodine estimations, will not accurately reflect thyroid function for up to 16 days following administration of iodinated contrast media. However, thyroid function tests not depending on iodine estimations, e.g., T3 resin uptake and total or free thyroxine (T4) assays are not affected.

Any test which might be affected by contrast media should be performed prior to administration of the contrast medium.

### **Laboratory Test Findings**

*In vitro* studies with animal blood showed that many radiopaque contrast agents, including iopamidol, produced a slight depression of plasma coagulation factors including prothrombin time, partial thromboplastin time, and fibrinogen, as well as a slight tendency to cause platelet and/or red blood cell aggregation.

Transitory changes may occur in red cell and leucocyte counts, serum calcium, serum creatinine, serum glutamic oxalacetic transaminase (SGOT), and uric acid in urine; transient albuminuria may occur.

These findings have not been associated with clinical manifestations.

### **Carcinogenesis, Mutagenesis, Impairment of Fertility**

Long-term studies in animals have not been performed to evaluate carcinogenic potential. No evidence of genetic toxicity was obtained *in vitro* tests.

### **Pregnancy: Teratogenic Effects**

Reproduction studies have been performed in rats and rabbits at doses up to 2.7 and 1.4 times the maximum recommended human dose (1.48 g/kg in a 50 kg individual), respectively, and have revealed no evidence of impaired fertility or harm to the fetus due to iopamidol. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

### **Nursing Mothers**

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when iopamidol is administered to a nursing woman.

### **Pediatric Use**

See **DOSAGE AND ADMINISTRATION** section.

## **ADVERSE REACTIONS**

The most frequently reported adverse reactions following intrathecal administration of iopamidol are headache, nausea, vomiting, and musculoskeletal pain. These reactions usually occur 1 to 10 hours after injection, almost all occurring within 24 hours. They are usually mild to moderate in degree, lasting for a few hours and usually disappearing within 24 hours. Rarely, headaches may be severe or persist for days. Headache is often accompanied by nausea and vomiting, and tends to be more frequent and persistent in patients not optimally hydrated. Backache, neck stiffness, numbness and paresthesias, leg or sciatic-type pain occurred less frequently, often in the form of a transient exacerbation of preexisting symptomatology. Transient alterations in vital signs may occur and their significance must be assessed on an individual basis.

The following table of incidence of reactions is based on clinical studies with ISOVUE-M (Iopamidol Injection) in about 686 patients.

<b>Adverse Reactions</b>		
<b>System</b>	<b>Estimated Overall Incidence</b>	
	<b>&gt; 1%</b>	<b>≤ 1%</b>
Body as a Whole	headache (16.4%)	pyrexia
		muscle weakness
		hot flashes
		malaise
		fatigue
Digestive	nausea (7.3%)	weakness
		diarrhea

Digestive	vomiting (3.6%)	heartburn leg cramps sciatica cervicobrachial irritation meningeal irritation
Musculoskeletal	back pain (2.2%) leg pain (1.4%) neck pain (1.1%)	radicular irritation lumbosacral other musculoskeletal pain involuntary movement burning sensation
Cardiovascular	hypotension (1.1%)	tachycardia hypertension chest pain emotional stress dizziness paresthesia confusion hallucinations
Nervous	none	lightheadedness syncope numbness cold extremities ataxia irritability
Urogenital	none	urinary retention
Respiratory	none	dyspnea
Skin and Appendages	none	rash
Miscellaneous	none	injection site pain

Other adverse effects reported in clinical literature for iopamidol include facial neuralgia, tinnitus, and sweating.

Major motor seizures have been reported in the clinical literature and since market introduction in the United States. Early onset of seizures (less than two hours) is indicative of early substantial intracranial entry. Transitory EEG changes occur and usually take the form of slow wave activity.

While not observed in controlled clinical studies with ISOVUE-M (Iopamidol Injection), the following adverse reactions may occur because they have been reported with ISOVUE-M and other nonionic water soluble contrast agents: cardiovascular (arrhythmias); pulmonary (apnea); bacterial meningitis, and aseptic meningitis syndrome; allergy or idiosyncrasy (chills, pruritus, nasal congestion, Guillain-Barre syndrome); CNS irritation (psycho-organic syndrome: mild and transitory perceptual aberrations such as depersonalization, anxiety, depression, hyperesthesia, disturbances in speech, sight, or hearing, and disorientation; in addition, hyperreflexia or areflexia, hypertonia or flaccidity, restlessness, tremor, echoacousia, echolalia, asterixis or dysphasia have occurred). Profound mental disturbances have rarely been reported (various forms and degrees of aphasia, mental confusion or disorientation); the onset is usually at 8 to 10 hours and lasts for about 24 hours without aftereffects. However, occasionally they have been manifest as apprehension, agitation or progressive withdrawal to the point of stupor or coma. In a few cases, these have been accompanied by transitory hearing loss or other auditory symptoms and visual disturbances (believed subjective or delusional). Persistent cortical loss of vision in association with convulsions, and ventricular block have been reported. Rarely, persistent though transitory weakness in the leg or ocular muscles has been reported. *Peripheral neuropathies* have been rare and transitory. They include sensory and/or motor or nerve root disturbances, myelitis,

persistent leg muscle pain or weakness, or sixth nerve palsy, or cauda equina syndrome. Muscle cramps, fasciculation or myoclonia, spinal convulsion, paralysis, or spasticity are unusual.

### **General Adverse Reactions To Contrast Media**

Reactions known to occur with parenteral administration of iodinated ionic contrast agents (see the listing below) are possible with any nonionic agent. Approximately 95 percent of adverse reactions accompanying the use of other water-soluble intravascularly administered contrast agents are mild to moderate in degree. However, life-threatening reactions and fatalities, mostly of cardiovascular origin, have occurred. Reported incidences of death from the administration of other iodinated contrast media range from 6.6 per 1 million (0.00066 percent) to 1 in 10,000 patients (0.01 percent). Most deaths occur during injection or 5 to 10 minutes later, the main feature being cardiac arrest with cardiovascular disease as the main aggravating factor. Isolated reports of hypotensive collapse and shock are found in the literature. The incidence of shock is estimated to be 1 out of 20,000 (0.005 percent) patients.

Adverse reactions to injectable contrast media fall into two categories: chemotoxic reactions and idiosyncratic reactions. Chemotoxic reactions result from the physicochemical properties of the contrast medium, the dose, and the speed of injection. All hemodynamic disturbances and injuries to organs or vessels perfused by the contrast medium are included in this category. During intrathecal use, there is a lower incidence of electroencephalographic changes as well as neurotoxicity by virtue of the intrinsic properties of the iopamidol molecule.

Idiosyncratic reactions include all other reactions. They occur more frequently in patients 20 to 40 years old. Idiosyncratic reactions may or may not be dependent on the amount of drug injected, the speed of injection, the mode of injection, and the radiographic procedure. Idiosyncratic reactions are subdivided into minor, intermediate, and severe. The minor reactions are self-limited and of short duration; the severe reactions are life-threatening and treatment is urgent and mandatory.

The reported incidence of adverse reactions to contrast media in patients with a history of allergy is twice that for the general population. Patients with a history of previous reactions to a contrast medium are three times more susceptible than other patients. However, sensitivity to contrast media does not appear to increase with repeated examinations. Most adverse reactions to intravascular contrast agents appear within one to three minutes after the start of injection, but delayed reactions may occur (see **PRECAUTIONS-General**).

Because measurable plasma levels are attained following the intrathecal administration of iopamidol, adverse reactions reported with the use of intravascular contrast agents are theoretically possible. These include:

*Cardiovascular:* vasodilation (feeling of warmth), cerebral hematomas, hemodynamic disturbances, sinus bradycardia, transient electrocardiographic abnormalities, ventricular fibrillation, petechiae.

*Digestive:* nausea, vomiting, severe unilateral or bilateral swelling of the parotid and submaxillary glands.

*Nervous:* paresthesia, dizziness, convulsions, paralysis, coma.

*Respiratory:* increased cough, asthma, dyspnea, laryngeal edema, pulmonary edema, bronchospasm, rhinitis.

*Urogenital:* osmotic nephrosis of proximal tubular cells, renal failure, pain.

*Special Senses:* perversion of taste; bilateral ocular irritation; lacrimation; itching; conjunctival chemosis, infection, and conjunctivitis.

*Endocrine:* Thyroid function tests indicative of hypothyroidism or transient thyroid suppression have been uncommonly reported following iodinated contrast media administration to adult and pediatric patients, including infants. Some patients were treated for hypothyroidism.

*Skin and Subcutaneous Tissue Disorders:* Reactions range from mild (e.g. rash, erythema, pruritus,

urticaria and skin discoloration) to severe: [e.g. Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN), acute generalized exanthematous pustulosis (AGEP) and drug reaction with eosinophilia and systemic symptoms (DRESS)]. Injection site pain usually due to extravasation and/or erythematous swelling, skin necrosis, urticaria.

The following reactions may also occur: neutropenia, thrombophlebitis, flushing, pallor, weakness, severe retching and choking, wheezing, cramps, tremors, and sneezing.

## OVERDOSAGE

A dose of 3000 mgI in adults and 2400 mgI in children is sufficient for most myelographic procedures. Doses above these levels may result in an increased frequency and severity of adverse reactions including seizures. However, in myelography, even use of a recommended dose can produce mental aberrations tantamount to overdosage, if incorrect management of the patient during or immediately following the procedure permits inadvertent early intracranial entry of a large portion of the medium.

Treatment of an overdose of an injectable radiopaque contrast medium is directed toward the support of all vital functions, and prompt institution of symptomatic therapy.

## DOSAGE AND ADMINISTRATION

In **adults** a solution that is approximately isotonic (ISOVUE-M 200) is recommended for examination of the lumbar region. For movement of the contrast medium to distant target areas the more concentrated ISOVUE-M 300 preparation should be used to compensate for dilution of ISOVUE-M (Iopamidol Injection) with cerebrospinal fluid.

The usual recommended adult dose range for Iopamidol is 2000-3000 mg iodine. Iopamidol formulated to contain more than 300 mgI/mL should not be used intrathecally in adults. The minimum dose needed to perform a procedure should always be used.

In **pediatric patients**, a solution that is approximately isotonic (ISOVUE-M 200) is recommended for all intrathecal procedures. In children, loss of contrast due to mixing on movement of the medium is less apt to occur because of their shorter spinal cord.

The usual recommended pediatric dose range for Iopamidol is 1400-2400 mg iodine. Iopamidol formulated to contain more than 200 mgI/mL should not be used intrathecally in children. The minimum dose needed to perform a procedure should always be used. See pediatric dosage table for recommended dosage.

Anesthesia is not necessary. However, young children may require general anesthesia for technical reasons. Premedication with sedatives or tranquilizers is usually not needed. In patients with a history of seizure activity who are not on anticonvulsant therapy, premedication with barbiturates or phenytoin should be considered.

Lumbar puncture is usually made between L3 and L4; if pathology is suspected at this level, the interspace immediately above or below may be selected. A lateral cervical puncture may also be used.

*Rate of Injection:* To avoid excessive mixing with cerebrospinal fluid and consequent loss of contrast as well as premature cephalad dispersion, injection must be made slowly over one to two minutes; the needle may then be removed.

An interval of at least 48 hours should be allowed before repeat examination; however, whenever possible five to seven days is recommended.

*As with all radiopaque contrast agents, only the lowest dose of ISOVUE-M necessary to obtain adequate visualization should be used. A lower dose reduces the possibility of an adverse reaction. Most procedures do not require use of either a maximum dose or the highest available concentration of ISOVUE-M; the combination of dose and ISOVUE-M concentration to be used should be carefully individualized, and factors*



such as age, body size, anticipated pathology and degree and extent of opacification required, structure(s) or area to be examined, disease processes affecting the patient, and equipment and technique to be employed should be considered. **Following are the usual recommended pediatric and adult doses of ISOVUE-M.**

The pediatric doses listed below, intended as a guideline, are based on age rather than weight because the brain and CSF capacity is independent of weight. Variations will depend on such factors as height, suspected pathology, the patient's condition, technique used, etc. (e.g. CT or standard radiology or movement of the contrast media directed distal to the site of injection).

**Pediatric Dosage Table**  
**ISOVUE-M 200 (200 mgI/mL)**

<b>Procedure</b>	<b>Age Years</b>	<b>Usual Recommended Dose (mL)</b>
Lumbar, thoracic myelogram	2-7	7-9
	8-12	8-11
	13-18	10-12

**Adult Dosage Table**

	<b>Concentration of Solution (mgI/mL)</b>	<b>Usual Recommended Dose (mL)</b>
Lumbar myelogram	200	10 to 15
Thoracic myelogram	200	10 to 15
Cervical myelogram	200	10 to 15
(via lumbar injection)	300	10
Cervical myelogram	200	10
(via lateral cervical injection)		
Total columnar myelography	300	10
CT cisternography	200	4 to 6
(via lumbar injection)		

Following subarachnoid injection, conventional radiography will continue to provide good diagnostic contrast for at least 30 minutes. At about one hour, diagnostic degree of contrast will not usually be available. However, sufficient contrast for CT myelography will be available for several hours. CT myelography following conventional myelography should be deferred for at least four hours to reduce the degree of contrast.

Aspiration of iopamidol is unnecessary following intrathecal administration (see **CLINICAL PHARMACOLOGY**).

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Iopamidol solutions should be used only if clear and within the normal colorless to pale yellow range. Discard any product which shows signs of crystallization or damage to the container-closure system, which includes the glass container, stopper and/or crimp.

It is desirable that solutions of radiopaque diagnostic agents for intrathecal use be at body temperature when injected. Withdrawal of contrast agents from their containers should be accomplished under aseptic conditions with sterile syringes. Spinal puncture must always be performed under sterile

conditions.

*Patients should be well hydrated prior to and following ISOVUE-M (Iopamidol Injection) administration.*

## **Suggestions for Usual Patient Management**

### **Preprocedure**

- **See WARNINGS** regarding discontinuation of neuroleptic agents.
- Maintain normal diet up to 2 hours before procedure.
- Ensure hydration-fluids up to time of procedure.

### **During Procedure**

- Use minimum dose and concentration required for satisfactory contrast.
- Inject slowly over 1 to 2 minutes to avoid excessive mixing.
- Abrupt or active patient movement causes excessive mixing with CSF.
- Instruct patient to remain *passive*. Move patient *slowly* and only as necessary.
- To maintain as a bolus, move medium to distal area *very slowly* under fluoroscopic control.
- In all positioning techniques keep the patient's head elevated above highest level of spine.
- Do not lower head of table more than 15° during thoraco-cervical procedures.
- In patients with excessive lordosis, consider lateral position for injection and movement of the medium cephalad.
- Avoid intracranial entry of a bolus.
- Avoid early and high cephalad dispersion of the medium.
- At completion of direct cervical or lumbo-cervical procedures, raise head of table steeply (45°) for about 2 minutes to restore medium to lower levels.

### **Postprocedure**

- Raise head of stretcher to at least 30° before moving patient onto it.
- Movement onto stretcher, and off the stretcher to bed, should be done slowly with patient completely passive, maintaining *head up* position.
- Before moving patient onto bed, raise head of bed 30° to 45° and maintain the patient in this position under close observation for 12 to 24 hours.
- Advise patient to remain still in bed, in *head up* position for the first 24 hours.
- Obtain visitors cooperation in keeping the patient quiet and in *head up* position, especially in first few hours.
- Encourage oral fluids and diet as tolerated.
- Antinauseants of the phenothiazine class should not be administered to treat postprocedural nausea or vomiting (see **WARNINGS**). Since persistent nausea and vomiting may result in dehydration, prompt consideration of volume replacement by intravenous fluids is recommended.

## **Drug Incompatibilities**

Many radiopaque contrast agents are incompatible *in vitro* with some antihistamines and many other drugs; therefore, no other pharmaceuticals should be admixed with contrast agents.

## **HOW SUPPLIED**

ISOVUE-M 200 (Iopamidol Injection 41%)

Ten 10 mL single dose vials (NDC 0270-1411-11)

Ten 20 mL single dose vials (NDC 0270-1411-25)

ISOVUE-M 300 (Iopamidol Injection 61%)

Ten 15 mL single dose vials (NDC 0270-1412-15)

## Storage

Store at 20-25° C (68-77° F). [See USP]. Protect from light.


Manufactured for  
Bracco Diagnostics Inc.  
Monroe Township, NJ 08831  
by BIPSO GmbH  
78224 Singen (Germany)

Revised October 2019

CL63A05

Isovue-M is a registered trademark of Bracco Diagnostics Inc.

Isovue-M 200:10x 10mL Box label  
NDC 0270-1411-11

1 box • 10 vials	10 mL each	NDC 0270-1411-11
<b>20% Organically Bound Iodine</b> <b>ISOVUE-M® 200</b> <b>Iopamidol Injection 41%</b> <b>Rx only</b>		
CE56701 - F.1/3000178		
<hr/>		
 1 box • 10 vials 10 mL each	NDC 0270-1411-11	<b>For Intrathecal Use</b> SEE INSERT FOR INDICATIONS AND DOSAGE INFORMATION Each mL of sterile, nonpyrogenic, aqueous solution provides 408 mg iopamidol with 1 mg tromethamine and 0.26 mg edetate calcium disodium; pH adjusted to 6.5-7.5 with hydrochloric acid and/or sodium hydroxide. Each mL contains approximately 0.029 mg (0.001 mEq) sodium and 200 mg organically bound iodine. <b>SINGLE DOSE VIALS • DISCARD UNUSED PORTION</b> <b>Keep cover closed to protect vials from exposure to light</b> <b>Store at 20-25°C (68-77°F) [See USP]</b>
<b>20% Organically Bound Iodine</b> <b>ISOVUE-M® 200</b> <b>Iopamidol Injection 41%</b> <b>Rx only</b>		
Manufactured for Bracco Diagnostics Inc. Monroe Twp., NJ 08831 by BIPSO GmbH, 78224 Singen (Germany)		
 (01)3030270141118(30)1		LOT: <div></div> EXP: <div></div>
		

Isovue-M 300:10x 15mL Box label  
NDC 0270-1412-15

1 box • 10 vials

15 mL each

NDC 0270-1412-15

30% Organically Bound Iodine

**ISOVUE-M<sup>®</sup> 300**

Iopamidol Injection 61%

Rx only

F.1/6057996



Bracco Diagnostics

1 box • 10 vials  
15 mL each

NDC 0270-1412-15

30% Organically Bound Iodine

**ISOVUE-M<sup>®</sup> 300**

Iopamidol Injection 61%

Rx only

Manufactured for Bracco Diagnostics Inc.  
Princeton, NJ 08543  
by BIPSO GmbH, 78224 Singen (Germany)

(01)30302701412153(30)1

**For Intrathecal Use**SEE INSERT FOR INDICATIONS AND DOSAGE  
INFORMATION

Each mL of sterile, nonpyrogenic, aqueous solution provides 612 mg iopamidol with 1 mg tromethamine and 0.39 mg edetate calcium disodium; pH adjusted to 6.5-7.5 with hydrochloric acid and/or sodium hydroxide. Each mL contains approximately 0.043 mg (0.002 mEq) sodium and 300 mg organically bound iodine.

**SINGLE DOSE VIALS • DISCARD UNUSED  
PORTION****Keep cover closed to protect vials from  
exposure to light****Store at 20-25°C (68-77°F) [See USP]**

LOT:

EXP:

**ISOVUE-M**

iopamidol injection, solution

**Product Information**

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:0270-1411
Route of Administration	INTRATHECAL		

**Active Ingredient/Active Moiety**

Ingredient Name	Basis of Strength	Strength
IOPAMIDOL (UNII: JR13W8 1H44) (IOPAMIDOL - UNII:JR13W8 1H44)	IOPAMIDOL	408 mg in 1 mL

**Inactive Ingredients**

Ingredient Name	Strength
-----------------	----------

tromethamine (UNII: 023C2WHX2V)			1 mg	in 1 mL
edetate calcium disodium (UNII: 25IH6R4SGF)			0.26 mg	in 1 mL
Packaging				
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:0270-1411-11	10 in 1 PACKAGE	12/31/1985	
1		10 mL in 1 VIAL, SINGLE-DOSE; Type 0: Not a Combination Product		
2	NDC:0270-1411-25	10 in 1 PACKAGE	12/31/1985	
2		20 mL in 1 VIAL, SINGLE-DOSE; Type 0: Not a Combination Product		
Marketing Information				
Marketing Category		Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NDA		NDA018735	12/31/1985	

## ISOVUE-M

iopamidol injection, solution

Product Information				
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:0270-1412	
Route of Administration	INTRATHECAL			
Active Ingredient/Active Moiety				
Ingredient Name		Basis of Strength	Strength	
IOPAMIDOL (UNII: JR13W8 1H44) (IOPAMIDOL - UNII:JR13W8 1H44)		IOPAMIDOL	612 mg in 1 mL	
Inactive Ingredients				
Ingredient Name		Strength		
tromethamine (UNII: 023C2WHX2V)		1 mg in 1 mL		
edetate calcium disodium (UNII: 25IH6R4SGF)		0.39 mg in 1 mL		
Packaging				
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:0270-1412-15	10 in 1 PACKAGE	12/31/1985	
1		15 mL in 1 VIAL, SINGLE-DOSE; Type 0: Not a Combination Product		

## Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NDA	NDA018735	12/31/1985	

**Labeler** - Bracco Diagnostics Inc (849234661)

**Registrant** - Bracco Diagnostics Inc (849234661)

## Establishment

Name	Address	ID/FEI	Business Operations
BRACCO IMAGING SPA		434384007	API MANUFACTURE(0270-1412, 0270-1411)

## Establishment

Name	Address	ID/FEI	Business Operations
BIPSO GmbH		342104149	MANUFACTURE(0270-1412, 0270-1411) , ANALYSIS(0270-1411, 0270-1412)

## Establishment

Name	Address	ID/FEI	Business Operations
Labor SL SE & Co. KG		314929072	ANALYSIS(0270-1411, 0270-1412)

## Establishment

Name	Address	ID/FEI	Business Operations
Patheon Italia S.p.A		434078638	MANUFACTURE(0270-1412, 0270-1411) , ANALYSIS(0270-1411, 0270-1412)

## Establishment

Name	Address	ID/FEI	Business Operations
BioChem Labor für biologische und chemische Analytik GmbH		318354230	analysis(0270-1411, 0270-1412)

Revised: 10/2020

Bracco Diagnostics Inc